NCT03990233 - A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

April 16, 2019

Primary Completion Date

April 17, 2023

Study Completion Date

April 30, 2025

Conditions

Solid Tumor, Adult

Interventions

DRUG

BI 765063

mAb antagonist to SIRPα receptor, a myeloid checkpoint inhibitor

DRUG

BI 754091

mAb antagonist to PD-1 receptor, a lymphocyte T checkpoint inhibitor

Trial Locations (8)

Institut Jules Bordet, Brussels

Universitair Ziekenhuis Brussel, Brussels

Universitair Ziekenhuis Gent, Ghent

Institut Claudius Regaud, Toulouse

Institut Bergonie, Bordeaux

Centre Léon Berard, Lyon

Institut Gustave Roussy, Villejuif

Hospital St Pierre, La Réunion